Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: Does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 3, 2011, Pages 280-285

  Pavlovsky, Carolina ^a   Giere, Isabel ^a   Moiraghi, Beatriz ^b   Pavlovsky, Miguel A ^a   Aranguren, Pedro Negri ^c   García, Juan ^d   Fernandez, Isolda ^a   Bengió, Raquel ^e   Milone, Jorge ^f   Labanca, Valentin ^g   Uriarte, Rosario ^h   Lombardi, Virginia ^a   Reinoso, Fernanda García ^a   Magarios, Alicia E ⁱ   Martinez, Lem ^h   Murro, Héctor ^j   Lastiri, Francisco ^k   Pavlovsky, Santiago ^a  

^a Fundacion para Combatir La Leucemia   (Argentina)

^b HOSPITAL RAMOS MEJÍA   (Argentina)

^c Instituto Privado de Hematología   (Argentina)

^d HOSPITAL PRIVADO   (Argentina)

^e ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^f HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^g Hospital Central Mendoza   (Argentina)

^h Specialized Techniques Laboratory   (Uruguay)

ⁱ HOSPITAL MACIEL   (Uruguay)

^j Ciudad Autonoma de Buenos Aires   (Argentina)

^k Grupo Argentino de Tratamiento de la Leucemia Aguda   (Argentina)

more..

Author keywords

Minimal residual disease; Prognostic factors; Real time quantitative polymerase chain reaction; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARGENTINA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG MONITORING; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE FREE SURVIVAL; SURVIVAL; URUGUAY; ADOLESCENT; CLINICAL TRIAL; GENETICS; MIDDLE AGED; MORTALITY; PROGNOSIS; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARGENTINA; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URUGUAY; YOUNG ADULT;

EID: 80053355373     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.03.016     Document Type: Article

References (22)

1. S.G. O'Brien, F. Guillot, and R.A. Larson Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004 (Pubitemid 36302244)
2. B.J. Druker, S. Tamura, and E. Buchdunger Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 1996 561 566
3. A. Hochhaus, S.G. O'Brien, and F. Guilhot Six year follow up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia 23 2009 1054 1061
4. M. Baccarani, J. Cortes, and F. Pane Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet J Clin Oncol 27 2009 6041 6051
5. R.D. Press, Z. Love, and A.T. Ashlie BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylatetreated patients with CML Blood 107 2006 4250 4256 (Pubitemid 43801348)
6. H. De Lavallade, J.F. Apperley, and J.S. Khorashad Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention to treat analysis J Clin Oncol 26 2008 3358 3363
7. D.M. Ross, S. Brandford, and S. Moore Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL Leukemia 20 2006 664 670
8. J. Cortes, M. Talpaz, and S. O'Brien Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate Clin Cancer Res 11 2005 3425 3432 (Pubitemid 40627896)
9. S. Branford, L. Fletcher, and N.C.P. Cross Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials Blood 112 2008 3330 3338
10. M. Baccarani, G. Saglio, and J. Goldman Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 2006 1809 1820 (Pubitemid 44394987)
11. D. Pinkel, T. Straum, and J.W. Gray Cytogenetic analysis using quantitative high sensitivity fluorescence hybridization Proc Natl Acad Sci U S A 83 1986 2934 2938 (Pubitemid 16041776)
12. J. Gabert, E. Beillard, and V.H. van der Velden Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia a Europe Against Cancer program Leukemia 17 2003 2318 2357 (Pubitemid 38072573)
13. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
14. R. Peto, M. Pike, and P. Armitage Design and analysis of a randomized clinical trial requiring prolonged observation of each patient II. Analysis and examples Br J Cancer 35 1977 1 39 (Pubitemid 8018922)
15. T.P. Hughes, A. Hochhaus, and S. Branford Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) Blood 116 2010 3758 3765 Epub 2010 Aug 2
16. F. Palandri, I. Iacobucci, and S. Soverini Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response Clin Cancer Res 15 2009 1059 1063
17. R.D. Press, C.H. Galderisi, and R. Yang A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response Clin Cancer Res 13 2007 6136 6143 (Pubitemid 350075073)
18. D. Marin, J. Kaeda, and R. Szydlo Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse Leukemia 19 2005 507 512 (Pubitemid 40521152)
19. D. Marin, D. Milojkovic, and E. Olavarria European LeukemiaNet criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor Blood 112 2008 4437 4444
20. H. Kantarjian, J. Shan, and D. Jones Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response J Clin Oncol 27 2009 3659 3663
21. S. Branford, N.C.P. Cross, and A. Hochhaus Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia Leukemia 20 2006 1925 1930 (Pubitemid 44614879)
22. V. Oehler, and J.P. Radich Monitoring patients with chronic myeloid leukemia receiving Abl tyrosine kinase inhibitor therapy Clin Lymphoma Myeloma 7 suppl 2 2007 S58 S63 (Pubitemid 46848469)